513 related articles for article (PubMed ID: 19900193)
41. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Neumiller JJ
Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
[TBL] [Abstract][Full Text] [Related]
42. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
43. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger J
J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
[TBL] [Abstract][Full Text] [Related]
45. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
46. Potential cardiovascular effects of incretin-based therapies.
Deacon CF; Marx N
Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
[TBL] [Abstract][Full Text] [Related]
47. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
48. [Incretin modulators, a new perspective in diabetes mellitus treatment].
Lupaşcu FG; Geangalău IM; Pânzariu A; Profire L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):630-4. PubMed ID: 23077965
[TBL] [Abstract][Full Text] [Related]
49. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
50. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
51. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
Angeli FS; Shannon RP
Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
[TBL] [Abstract][Full Text] [Related]
52. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
53. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
54. Incretin-based therapies: review of current clinical trial data.
Peters A
Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
[TBL] [Abstract][Full Text] [Related]
55. Incretin-based therapies, glucometabolic health and endovascular inflammation.
Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
[TBL] [Abstract][Full Text] [Related]
56. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
57. Incretins: what is known, new and controversial in 2013?
Burcelin R; Thorens B;
Diabetes Metab; 2013 Apr; 39(2):89-93. PubMed ID: 23523140
[TBL] [Abstract][Full Text] [Related]
58. Incretin-based therapies: where will we be 50 years from now?
Meier JJ; Nauck MA
Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
[TBL] [Abstract][Full Text] [Related]
59. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
[TBL] [Abstract][Full Text] [Related]
60. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP; Pratley RE
Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
